Thus, lineage switch following pressure on the B-cell lineage by CD19 CAR can be recapitulated through ablation of master regulators of B-cell development but only in ALL with the capacity to utilize this mechanism for resistance to CD19-targeted immunotherapy. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.